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Abstract: The term “cryptome” refers to the subset of cryptic peptides with bioactivities 
that are often unpredictable and very different from the parent protein. These cryptic 
peptides are generated by proteolytic cleavage of proteases, whose identification in vivo 
can be very challenging. In this work, we show that insulin-degrading enzyme (IDE) is 
able to degrade specific amino acid sequences present in the neuropeptide pro-NPFFA 
(NPFF precursor), generating some cryptic peptides that are also observed after incubation 
with rat brain cortex homogenate. The reported experimental findings support the 
increasingly accredited hypothesis, according to which, due to its wide substrate 
selectivity, IDE is involved in a wide variety of physiopathological processes. 
Keywords: IDE; neuropeptide; metalloprotease; cryptome; mass spectrometry; surface 
plasmon resonance 
 
1. Introduction 
The terms “cryptic peptides” and “cryptome” have been used for a few decades to indicate the pools of 
peptides that are formed by the proteolytic action of peptidases on precursor proteins. In many cases, it has 
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been demonstrated that such peptides have biological properties and activities that are distinct from  
their precursor proteins [1,2] and, for this reason, very recently, the investigation of the biochemical 
mechanisms, through which they are generated, has been pursued by many researchers [3,4]. The word 
“cryptomics” has also been introduced to describe the systemic approach of finding crypteins in vitro [5]. 
In this scenario, cryptic peptides, which are normally present in the brain, i.e., neuropeptides (NPs), 
seem to have very important modulatory roles in controlling our mood, energy levels, pain and 
pleasure perception, etc. [6]. NPs are considered the largest class of messengers in the central nervous 
system (CNS), and as other cryptic peptides, their formation and homeostasis are tightly regulated by 
the action of various proteases acting on the precursor proteins from which they are generated [7]. 
Particularly, NPs released from the NPFF precursor (pro-NPFFA) have been recently reported to be 
involved in several processes, such as pain transmission [8], the action of drugs of abuse [9], 
cardiovascular functions, appetite, thirst and body temperature [10]. Very recently, we have reported 
the discovery of a novel amino acid sequence derived from pro-NPFFA, NAWGPWSKEQLSPQA, 
named NPNA, from neuropeptide (NP) and its flanking amino acids (N and A), which is able to block 
the expression of conditioned place preference induced by morphine and reverses the antinociceptive 
activity of morphine in the tail-immersion test in rats [11]. This peptide, in contrast to the  
previously described fragments derived from pro-NPFFA (i.e., NPFF: FLFQPQRF-NH2; NPAF: 
AGEGLSSPFWSLAAPQRF-NH2; NPSF: SLAAPQRF-NH2), does not have the PQRF-amidated 
sequence at the C-terminus [12]. Moreover, exogenous NPNA (residues 85–99 in pro-NPFFA) [11], apart 
from having NPFF-like behavioral activity in rats [11], also modulates the activity of genes coding for 
three α subunits of the G protein in three different brain regions [13]. However, the exact processes by 
which NPNA and other NPs derived from pro-NPFFA are formed remain unclear. Because of the wide 
variety of proteases present in the brain, the understanding of the proteolytic processes, which are 
responsible for the formation and homeostasis of these NPs, represents a very important and 
challenging task. 
Insulin-degrading enzyme (IDE) is a zinc metalloprotease that has recently attracted the interest of 
the scientific community because of its broad specificity for peptide substrates [14–17] and its 
ubiquitous localization [18]. Indeed, both factors make this enzyme potentially available for a variety of 
biomolecular processes involved in homeostatic and pathological conditions, such as Alzheimer’s disease 
(AD). In experiments using IDE-deficient mice, Aβ catabolism is considerably reduced with an increase  
of endogenous Aβ [19], and IDE degrades Aβ in conditioned medium from neuronal cultures [20].  
Moreover, the transgenic overexpression of IDE results in lowered Aβ levels and reduced or 
completely prevented the plaque formation observed in AD [21]. More recently, it has been reported 
that IDE, apart from regulating insulin [22] and Aβ peptides levels [23], is overexpressed in vivo in 
tumors of the CNS, and a novel role for IDE as a heat shock protein has also been proposed [24]. 
In this work, we wanted to provide insight into the proteolytic processes regulating the metabolism 
of some of the abovementioned NPs derived from pro-NPFFA. For this purpose, we have applied 
electrospray ionization mass spectrometry (ESI-MS) for the analysis of the NPs generated during the 
incubation of various precursor NPs in brain cortex homogenates. We have then investigated the 
cryptic peptides that are generated by the digestion with IDE of the same bioactive NPs derived from 
pro-NPFFA. The experimental findings indicate that IDE is involved in the metabolism of NPs derived 
from pro-NPFFA. 
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2. Results and Discussion 
Firstly, we wanted to elucidate the possible mechanisms responsible for NPNA proteolysis.  
The investigation of this process, consisting of intracellular degradation of peptides by enzymes present 
in brain cortex, enabled us to confirm the biological activity of the tested compounds in analgesia and 
drug dependence [13]. For this purpose, proteases metabolizing NPNA in rat brain cortex were applied. 
Products of proteolysis were identified using ESI-MS and are summarized in Table 1. Based on the 
integration of the peak area of newly-created peptides, only three fractions, with the highest product 
intensity, were taken into account for further time course metabolic process (Figure 1). The highest 
product intensity was observed after 4 h cleavage (the time-dependent data are reported in  
Figure S1). The activity of enzymes is not specific: proteases cleave peptides mainly at the carboxyl side 
of tryptophan and leucine [25]. Therefore, these results suggest the existence of several peptidases 
converting NPNA peptide to shorter bioactive fragments responsible for the analgesic activity of this rat 
cryptein. In this case, we have confirmed that IDE is not responsible for NPNA degradation, because 
incubation with IDE does not produce any NPNA fragments at all incubation times investigated (up to 
24 h, the mass spectrum was the same as the one recorded without IDE; data not shown).  
One could argue that the absence of degradation could be attributed to the short length of the peptide, 
because, with some exceptions, most IDE substrates are considerably longer than 15 amino acids [16]. 
This common feature among IDE substrates has been explained by considering that IDE has an exosite 
that is an evolutionary-conserved substrate-binding site 30 Å away from the catalytic groove and serves 
as an anchor to attach the N-terminal end of IDE substrates [26]. In order to assess if the absence  
of proteolytic fragments is due to the short length of the substrate or to the lack of sequence  
specificity, we have carried out the same proteolytic experiment using another NP, named NPSA 
(SAWGSWSKEQLNPQA {1–15}), which has the same number of amino acids as NPNA, but contains 
three substitutions at Positions 1, 5 and 12 and is obtained from mouse pro-NPFFA [12]. As is reported in 
Figure 2, one main cleavage site is observed in this case (between Trp6 and Ser7; fragments at  
m/z 693.2 and 1014.3 corresponding, respectively, to SAWGSW and SKEQLNPQA were confirmed by 
MS/MS experiments; see Figure S2). Degradation of NPSA by IDE is time-dependent and is completed 
within two hours for a solution that has (IDE) = 1/6000 (NPSA), as is confirmed by the disappearance of 
the NPSA molecular peak from the mass spectrum (Figure 2b). These results demonstrate that IDE is able 
to degrade peptides as short as 15 amino acids in a sequence-specific manner. 
Table 1. Products of NPNA (NAWGPWSKEQLSPQA {1–15}) metabolism in major 
fractions from rat brain cortex separation. The most intense products on the mass spectrum 
(not shown) are marked in bold. 
Fraction No. Peptide Fragment Sequence m/z Value 
23 {1–11} NAWGPWSKEQL 658.5 (2+) {12–15} SPQA 402.4 
26 
{1–11} NAWGPWSKEQL 658.5 (2+) 
{1–3} NAW 390.4 
{4–6} GPW 359.4 
{7–11} SKEQL 604.6 
{12–15} SPQA 402.4 
35 {4–15} GPWSKEQLSPQA 664.5 (2+) 
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Figure 1. Intensity distribution of major products of NPNA (NAWGPWSKEQLSPQA {1–15}) 
metabolism in Fractions 1–45 from rat brain cortex separation on an Econo-Pac Q column. 
 
Figure 2. Electrospray ionization (ESI) mass spectrum obtained for a PBS solution 
incubated for 2 h at 37 °C containing (a) (NPSA 1–15) = 50 μM; (b) (NPSA 1–15) =  
50 μM and (IDE) = 8 nM; while in (a), only the full-length peptide is detected (with the 
addition of H+, Na+ and K+); in (b), the two main fragments derived from cleavage site 
Trp6–Ser7 are detected, confirming the proteolytic action of IDE on this peptide. 
 
However, even if IDE is not able to degrade NPNA, we have investigated if it is able to  
produce NPNA or some other peptides from longer pro-NPFFA fragments. For this purpose, a  
new peptide sequence (PQRFGRNAWGPWSKEQLSPQAREFW) derived from rat pro-NPFFA was 
tested as a possible IDE substrate. PQRFGRNAWGPWSKEQLSPQAREFW is an elongated form of 
NPNA and is named NPPW 1–25 from now on. NPPW 1–25 was incubated with IDE, and the results 
are reported in Figure 3. It can be observed that IDE is able to produce several fragments derived from 
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cleavage sites Gly5–Arg6, Ala8-Trp9, Gly10-Pro11 and Gln20-Ala21. The detected fragments confirm 
the proteolytic action of IDE on NPPW 1–25 (fragments were confirmed by MS/MS experiments; as 
an example, see the fragmentation of peak at m/z 1442.7 assigned to fragment WGPWSKEQLSPQ in 
Figure S3). It is important to highlight that the major cleavage site is Gln20–Ala21, as the only peptide 
fragment that is not truncated at Gln20 (PWSKEQLSPQAREFW, that is NPPW 11–25) is generated 
only at longer incubation times (more than 2 h; data not shown). Therefore, in our experimental 
conditions, some peptide fragments different from NPNA were produced by the action of IDE on 
NPPW 1–25. 
Figure 3. ESI mass spectrum obtained for a PBS solution incubated for 8 h at 37 °C 
containing (a) (NPPW 1–25) = 50 μM; (b) (NPPW 1–25) = 50 μM and (IDE) = 8 nM; 
while in (a), only the full-length peptide is detected; in (b), the fragments derived from 
cleavage sites Gly5–Arg6, Ala8–Trp9, Gly10–Pro11 and Gln20–Ala21 are detected, 
confirming the proteolytic action of IDE on this peptide. Other peaks assigned to the same 
fragments with the addition of Na+ and K+ are not labelled for simplicity. 
 
We then tested the degradation of NPPW 1–25 peptide after incubation with rat brain homogenate, 
with and without the addition of amastatin. The latter was added to exclude the activity of 
aminopeptidases that are abundant in CNS. Such activity is responsible, among others, for the 
inactivation of opioid peptides, by truncation of the N-terminal Tyr, thus preventing binding to opioid 
receptors. Indeed, the same results were recorded with and without this inhibitor. In Table 2, the 
assignment of the peptide fragments detected is reported, while in Figure 4, a quantitative detection  
of their amounts at different incubation times is also shown. Notably, the most abundant peak is  
NPPW 1–20, which indicates Gln20–Ala21 as the major cleavage site. Therefore, this result suggests 
that one of the proteases responsible for the degradation of NPPW 1–25 is very likely to be IDE, as the 
above reported in vitro experiments show that this enzyme is able to cleave the peptide at the same 
cleavage site, producing fragment PQRFGRNAWGPWSKEQLSPQ at high abundance, and is not 
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inhibited by amastatin. A further proof of this thesis could be obtained by applying selective IDE 
inhibitors that could become more easily available in the near future [27]. 
Figure 4. ESI-MS quantitative detection of peptide fragments produced by the degradation 
of (NPPW 1–25) in rat brain homogenate (see Table 2) at different incubation times.  
Note that the most abundant peptide fragment is NPPW 1–20. The same result was 
obtained with and without the addition of amastatin. 
 
Table 2. Products of NPPW 1–25 in major fractions from rat brain cortex separation.  
The most intense fragment on the mass spectrum is NPPW 1–20 (see Figure 4). 
Peptide Mass (Da) Ion m/z Charge Sequence 
{1–20} 2368.2 790.4 3+ PQRFGRNAWGPWSKEQLSPQ 
{1–21} 2439.2 814.1 3+ PQRFGRNAWGPWSKEQLSPQA 
{1–23} 2724.4 909.1 3+ PQRFGRNAWGPWSKEQLSPQARE 
{3–25} 2832.4 945.1 3+ RFGRNAWGPWSKEQLSPQAREFW 
{7–25} 2316.1 773.1 3+ NAWGPWSKEQLSPQAREFW 
Finally, in order to further characterize the interaction between IDE and the NPs reported above, we 
have immobilized IDE, as described in the Materials and Methods, and measured its affinity with the 
different NPs by Surface Plasmon Resonance (SPR). In Figure 5, the OneStep binding curves together 
with the simulations curves that produced the kinetic parameters reported in Table 3 are shown. It is 
important to highlight that, in order to fit the experimental curves, the two binding site interaction 
model was necessary in the case of NPSA and NPPW peptides. Particularly, as is shown in Table 3, 
the KD values obtained are within the same order of magnitude of other IDE substrates [15,28]. The 
NPPW 1–25 peptide has the lowest KD values for both binding sites, confirming a higher affinity of IDE 
toward this elongated sequence. The above reported MS results show that NPNA is the only peptide 
among the three investigated that is not cleaved by IDE and, interestingly, is also the only one whose 
SPR OneStep curve could be better fitted by the one binding site model. Therefore, it is easy to speculate 
that, in order to be an IDE substrate, a peptide has to bind to the enzyme by two binding sites, as has 
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already been proposed by other groups [26]. However, such speculation needs to be further confirmed by 
applying the same SPR experimental procedure using many other different substrates. 
Table 3. Kinetic parameters obtained by SPR experiments for the NPs indicated. Res SD 
values refer to the residuals. 
Peptide kon1 koff1 KD1 kon2 koff2 KD2 Res SD 
NPNA 139.7 0.5562 3.98161 mM – – – 2.578 
NPSA 18.66 0.6637 35.55 mM 2.476 0.614 247.97 μM 3.521 
NPPW 3180 0.354 111 μM 19 0.032 170 μM 0.647 
Figure 5. SPR curves obtained for the OneStep interaction of immobilized IDE and the 
indicated NPs. The inset is a zoom of the boxed area. Black lines are experimental data, 
while grey dashed lines are simulations obtained as discussed in the text. 
 
3. Materials and Methods 
3.1. Peptide Synthesis 
NPNA was synthesized by the standard Fmoc-solid phase peptide synthesis method and purified by 
HPLC, using a preparative reverse-phase C18 column (Hypersil Gold 250 × 20 mm, Thermo Scientific, 
Bremen, Germany). The purity of peptide was greater than 98% and was tested by ESI-MS (Esquire 
3000, Bruker Daltonics, Bremen, Germany). 
3.2. Tissue Preparation 
Brain cortices were rapidly removed from the male Wistar rats (150–200 g) and frozen immediately 
on dry ice. Tissues were kept at −80 °C until assayed. Brain was homogenized in an ice-cold 20 mM 
Tris–HCl buffer, pH 7.5, and diluted 1:6. The obtained homogenate was centrifuged twice at 14,000× g 
for 10 min at 4 °C. The supernatant was divided into small aliquots and kept frozen at −80 °C until 
usage, as further purification did not change the outcome of the experiments. 
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3.3. Enzyme Separation from Rat Brain Homogenate 
Enzymes present in the rat brain homogenate were separated on the ion-exchange column Econo-Pac 
High Q (resin volume: 5 mL; Bio-Rad, Berkeley, CA, USA). Gradient separation was performed by the 
HPLC system Prominence LC-20 AD with a Photodiode Array Detector SPD-M20A (Shimadzu, Tokyo, 
Japan). The sample volume loaded on the column was 1 mL. The mobile phase consisted of 20 mM  
Tris–HCl buffer, pH 7.5, and a gradient of NaCl from 0 to 500 mM in 60 min was used. The total flow rate 
was 1 mL/min. One-point-five-milliliter fractions were collected during the separation and stored in −80 °C 
prior to further experiments. 
3.4. Enzyme Assay of Homogenized Brain 
Enzyme assays were performed in 0.5-mL Eppendorf tubes. Each homogenized brain fraction was 
diluted 1:5 with 20 mM Tris–HCl buffer, pH 7.5, and the reaction was initiated by the addition of 5 μg 
of NPNA and continued by mixing at 37 °C for 120 min (or for 300 min for preparing time course 
metabolic process). Five-microliter aliquots were taken from the incubation mixture, acidified by 30% 
MeOH with 0.1% FA and analyzed by ESI-MS (Bruker Esquire 3000) equipped with an autosampler  
(Famos, Thermo Scientific, earlier LC-Packings, Bremen, Germany). MS/MS analysis was performed 
to confirm the sequence of the released fragments. Quantitation of the enzyme activity was performed 
by integration of the peak area of formed products on the mass chromatogram. The samples were 
incubated with and without amastatin, an aminopeptidase inhibitor. 
3.5. Insulin-Degrading Enzyme (IDE) in Vitro Assays 
IDE, His-Tag, rat, recombinant, from Spodoptera frugiperda, was purchased from Calbiochem 
(Milan, Italy), and its activity was verified by carrying out enzymatic digestion of insulin solutions 
according to the experimental procedure previously reported [29]. Methanol (MeOH), formic acid 
(FA), Tris–HCl buffer, phosphate buffered saline (PBS) buffer and all chemicals used were purchased 
from Sigma–Aldrich. ZIPTIP C18 was purchased from Millipore (Milan, Italy). IDE enzymatic assays 
were carried out by incubating the enzyme solution (0.4 μM) at 37 °C with the peptide solution at the 
indicated concentration. After purification with ZIPTIP C18, 3 μL of the resulting solution were mixed 
with 50 μL of water and 50 μL of MeOH and injected into the mass spectrometer at 5 μL/min. ESI-MS 
experiments were performed by using a Finnigan LCQ DECA XP PLUS ion trap spectrometer 
operating in the positive ion mode and equipped with an orthogonal ESI source (Thermo Electron 
Corporation, Madison, WI, USA). Sample solutions were injected into the ion source using nitrogen  
as the drying gas. The mass spectrometer operated with a capillary voltage of 46 V and capillary a 
temperature of 250 °C, while the spray voltage was 4.3 kV. MS/MS data were interpreted by using the 
“Molecular Weight Calculator” software by Matthew Monroe freely available on the web [30]. 
3.6. Surface Plasmon Resonance Measurements 
Surface plasmon resonance measurements were carried out on a SensiQ Pioneer instrument,  
and all reagents used were from Sigma. IDE was immobilized on a COOH5 biosensor chip from  
ICx Nomadics (Oklahoma City, OK, USA). Briefly, covalent immobilization was obtained by  
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amine coupling of the lysine-free amino groups and terminal amines of the protein, as described  
elsewhere [31,32]. Particularly, 400 μL of IDE solution at 100 μg/mL in 10 mM acetate buffer,  
pH 3.8, were used for the immobilization on a previously activated surface having reactive 
succinimide ester groups obtained by using 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide (EDC) 
and N-hydroxysuccinimide (NHS) solution, freshly prepared ((EDC) = 0.4 M, (NHS) = 0.1 M). NaOH 
50 mM was used for regeneration of the surface, while the buffer used for the interaction of IDE with 
the peptides solutions was obtained by mixing N-(2-vsHydroxyethyl)piperazine-N'-(2-ethanesulfonic 
acid) and sodium salt (0.01 M HEPES, 0.15 M NaCl, pH 7.4). The OneStep approach [33] was applied 
to investigate the interactions between immobilized IDE and NPs and the initial concentrations of the 
NPSA, NPNA and NPPW peptides solutions were 74, 74 and 150 μM, respectively. The software Qdat 
was used to fit the experimental curves according to the equations given in [33,34]. Briefly, the signal 
response (R) versus time (t) is given by: 
dR/dt = kon × C × Rmax − (kon × C + koff) × R (1)
where C is the analyte concentration, Rmax is the capacity of immobilized ligand and kon, koff are the 
kinetic constants. For an injection beginning at time t0 and ending at t1, we have: 
c1 = C × kon + koff (2)
For t0 < t < t1 (association phase): 
R (t) = C × kon × Rmax × (1 − exp (−c1 × (t − t0)))/c1 (3)
For t > t1 (dissociation phase): 
R (t) = C × kon × Rmax × (1 − exp (−c1 × (t1 − t0)))/c1 × exp (−koff × (t − t1)) (4)
For multi-site kinetics, the total response is given as the sum of response from each individual site. 
Therefore, for Site 1, R1 (t, kon1, koff1, Rmax1), and Site 2, R2 (t, kon2, koff2, Rmax2); total response  
R (t) = R1 + R2. Fitting is performed using standard Levenberg–Marquardt nonlinear least squares 
optimization, minimizing the sum-squared error of the difference between the model and the 
experimental data. 
4. Conclusions 
NPs precursors are inactive and contain multiple copies of various biologically-active sequences. 
However, the biomolecular mechanisms responsible for the formation of the active peptides are very 
often obscure. In this work, we have investigated the capability of IDE to degrade various amino acidic 
sequences “hidden” in the rat and mouse pro-NPFFA precursors, and we have compared the results 
with those obtained after incubation with rat brain cortex homogenate. Particularly, we have found that 
IDE is not able to degrade NPNA, while the latter peptide generates several fragments when incubated 
with rat brain cortex. The results show that the activity of isolated enzymes is not specific, as several 
proteases cleave NPNA mainly at the carboxyl side of the tryptophan and leucine, converting NPNA 
peptide to shorter bioactive fragments responsible for the analgesic activity of this rat cryptein. 
Nevertheless, we have identified one major cleavage site by IDE in a mouse NP of the same amino 
acidic length, that is NPSA. These results demonstrate that IDE is capable of the degradation of 
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substrates that are as short as 15 amino acidic residues, but is also sequence specific. However, as NPNA 
is degraded in rat brain cortex, IDE does not seem to be involved in this process. Indeed, although IDE’s 
ability to degrade peptide is not highly substrate specific, this enzyme does not degrade all peptides [35], 
and it is ubiquitously present in the nervous tissue. For this reason, we decided to explore the 
possibility that IDE is indeed involved in the proteolysis of NPFF fragments, in particular cryptic 
sequences, as they became an emerging source of potential therapeutics. As the results of our work 
show, there are several enzymes involved in the cleavage of NPNA. The key point of our work was 
therefore to reveal possible fragments generated in the brain. This is important for two reasons. The 
first is purely pharmacological, because NPNA analogs can be used as a potential therapy in drug 
dependence [12]. Another purpose was to investigate the potential NPNA endogenous fragments that 
may exist in the brain. Therefore, this work did not aim at the isolation and identification of such 
sequences, because this requires specific antibodies and affinity chromatography. In turn, antibodies 
can be raised only when the appropriate fragments have been recognized. 
On the other hand, we have found that the most abundant peptide fragment (PQRFGRNA 
WGPWSKEQLSPQ) that is generated when the elongated peptide sequence NPPW 1–25 is incubated 
with IDE is also produced in a high amount when the same peptide is incubated in rat brain cortex. The 
latter result indicates that IDE is very likely to be involved in the degradation of NPPW 1–25 in vivo. 
This finding tends to prove the recently proposed hypothesis according to which IDE has many 
different roles in vivo [24], which have still to be unveiled. 
Finally, the KD constants for the interaction between IDE and the three investigated NPs have been 
obtained by SPR analysis. The results show that the SPR curve for NPNA, the only NP among the 
scrutinized peptides that is not degraded by IDE, can be better fitted by using the one binding site 
model. On the contrary, the SPR curves recorded for the interaction between IDE and the other two 
peptides, NPSA and NPPW, require the two binding sites model to be fitted. Such results could be 
explained by considering that, in order to act as a degrading enzyme, IDE has to bind the substrate 
through two different binding sites. In the cases explored above, it is likely that the second binding site 
of IDE is sitting between the last amino-acids of the NPPW peptide (REFW) of the sequence, as they 
do not belong to the NPNA sequence and constitute the target of IDE. However, such speculation 
needs to be further verified by studying the interaction of IDE with many other biomolecules. 
Supplementary Materials 
Supplementary Figures can be found at http://www.mdpi.com/1422-0067/15/9/16787/s1. 
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